M. Durante
Hospital Del Mar(ES)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Radiation Therapy and Dosimetry, Celiac Disease Research and Management, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19(2020)1,420 cited
- → Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19(2021)941 cited
- → Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis(2019)219 cited
- → A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors(2014)125 cited
- → First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies(2015)109 cited
- → A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours(2013)88 cited
- → Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis(2020)61 cited
- → A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer(2013)45 cited
- → A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.(2014)27 cited
- → 882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study(2018)19 cited